Endocannabinoid and Prostanoid Crosstalk in Pain

Buisseret, Baptiste;Al Houayek, Mireille;Guillemot-Legris, Owein;Muccioli, Giulio
(2019) Trends in Molecular Medicine — Vol. 25, p. 882-896 (2019)

Files

Buisseret_TMM2019.pdf
  • Open Access
  • Adobe PDF
  • 1.54 MB
Download

Details

Authors
Abstract
Interfering with endocannabinoid (eCB) metabolism to increase their levels is a proven anti-nociception strategy. However, because the eCB and prostanoid systems are intertwined, interfering with eCB metabolism will affect the prostanoid system and inversely. Key to this connection is the production of the cyclooxygenase (COX) substrate arachidonic acid upon eCB hydrolysis as well as the ability of COX to metabolize the eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) into prostaglandin-ethanolamides (PG-EA) and prostaglandin-glycerol esters (PG-G), respectively. Recent studies shed light on the role of PG-Gs and PG-EAs in nociception and inflammation. Here, we discuss the role of these complex systems in nociception and new opportunities to alleviate pain by interacting with them.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Buisseret, B., Al Houayek, M., Guillemot-Legris, O., & Muccioli, G. (2019). Endocannabinoid and Prostanoid Crosstalk in Pain. Trends in Molecular Medicine, 25, 882-896. https://doi.org/10.1016/j.molmed.2019.04.009 (Original work published 2019)